Vistagen Therapeutics, Inc.

Good afternoon, ladies and gentlemen, and welcome to the Vistagen Therapeutics Fiscal Year 2025 Second Quarter Corporate Update Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, November 7, 2024. I would now like to turn the call over to Mr. Mark McPartland, Senior Vice President, Investor Relations at Vistagen. Please go ahead.

Thank you, Operator. Good afternoon, everyone, and welcome to Vistagen's fiscal year 2025 second quarter corporate update conference call and webcast. Earlier this afternoon, we filed our quarterly report with the Securities Exchange Commission on the SEC Form 10-Q for our second quarter that ended September 30, 2024. And we also issued a press release providing an overview of our progress across our lead neuroscience programs. We encourage you to review the release and our 10-Q, which can be found in the investor section of our website. We will make forward-looking statements regarding our business during today's call based on our current expectations and information. These forward-looking statements speak only as of today, except as required by law, we do not assume any duty to update any forward-looking statements made today or in the future. Of course, forward-looking statements involve risks, uncertainties, and our actual results could differ materially from those anticipated by any forward-looking statements we make today. Additional information concerning risk factors that could affect our business and financial results is included in our fiscal year 2025 second quarter form 10Q for the period ending September 30th, 2024, and in future filings that we make with the SEC from time to time, all of which, again, are on our website in the investor section on the SEC website. With the formalities completed, I would like to warmly welcome our stockholders, sell-side analysts, and others interested in our programs and progress. I'm joined on our call today by Sean Singh, our Chief Executive Officer, Cindy Anderson, our Chief Financial Officer, and Josh Prince, our Chief Operating Officer. Sean will discuss our recent highlights in our lead neuroscience programs, and Cindy will discuss our second quarter financial results. At the conclusion of our prepared remarks, as the operators already noted, there will be a brief opportunity for questions from the cell site analysts. As a reminder, this call is being webcast and will be available for replay after completion. The replay link, again, can be found on our website's events section.

Sean?